| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-4, IL-4, B-cell stimulatory factor 1, BSF-1, Binetrakin, Lymphocyte stimulatory factor 1, Pitrakinra, IL4 |
| Entrez GeneID | 3565 |
| WB Predicted band size | 17.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This L4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 122-150 amino acids from the C-terminal region of human L4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL4抗体的3篇代表性文献示例(注：内容为模拟虚构，实际文献请通过学术数据库查询)：
1. **"IL-4 Antibody Therapy Attenuates Allergic Inflammation in a Murine Asthma Model"**
- **作者**: Smith A, et al.
- **摘要**: 研究证明，抗IL-4单克隆抗体通过阻断IL-4与受体结合，显著减少小鼠哮喘模型中的嗜酸性粒细胞浸润和气道高反应性，为过敏性疾病治疗提供新策略。
2. **"Targeting IL-4/IL-13 Signaling in Cancer Immunotherapy"**
- **作者**: Brown K, et al.
- **摘要**: 探讨IL-4/IL-13通路在肿瘤微环境中的作用，发现使用双特异性抗体抑制该通路可增强抗肿瘤T细胞活性，抑制实体瘤生长。
3. **"Engineering a High-Affinity Anti-IL-4 Antibody for Inflammatory Disease Treatment"**
- **作者**: Zhang Y, et al.
- **摘要**: 通过噬菌体展示技术优化抗IL-4抗体亲和力，体外实验显示优化后的抗体能更有效中和IL-4.并在类风湿性关节炎模型中减轻关节炎症。
4. **"IL-4 Neutralization Alters Macrophage Polarization in Autoimmunity"**
- **作者**: Lee J, et al.
- **摘要**: 研究抗IL-4抗体对巨噬细胞极化的影响，发现其可抑制M2型巨噬细胞分化，逆转系统性红斑狼疮模型中的免疫失衡。
如需真实文献，建议检索PubMed、Google Scholar等平台，关键词：**IL-4 antibody, therapeutic targeting, interleukin-4 blockade**。
Interleukin-4 (IL-4) is a pleiotropic cytokine primarily produced by activated T helper 2 (Th2) cells, mast cells, and basophils. It plays a central role in regulating immune responses, particularly in promoting Th2 differentiation, IgE production, and anti-parasitic or allergic inflammation. IL-4 exerts its effects by binding to cell surface receptors, either the type I receptor (IL-4Rα paired with γc chain) or type II receptor (IL-4Rα with IL-13Rα1), activating downstream signaling pathways like JAK-STAT.
IL-4 antibodies are immunoglobulins designed to specifically target and neutralize IL-4 or its receptors. Developed as research tools and therapeutic agents, they include monoclonal antibodies (e.g., Dupilumab) that block IL-4Rα, thereby inhibiting signaling of both IL-4 and IL-13. Such antibodies have shown clinical efficacy in Th2-mediated diseases, including moderate-to-severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. In research, IL-4 antibodies are widely used in ELISA, flow cytometry, and functional studies to dissect IL-4's roles in immune regulation, inflammation, and tissue remodeling. Neutralizing IL-4 antibodies also help investigate mechanisms underlying allergic reactions, autoimmune disorders, and tumor microenvironments where IL-4 may promote immunosuppression. Their development reflects ongoing efforts to modulate cytokine networks for precision immunotherapy.
×
